Figure 1 | Scientific Reports

Figure 1

From: Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care

Figure 1

Patient flow chart. aPatients ever followed up in SCQM as adult (18 + years) RA patients by participating institutions. bNo exposure to single biologic (b) or targeted synthetic (ts) disease-modifying antirheumtic drugs (DMARDs) during study participation that started after diagnosis, after 18th birthday, and during which the patient was at risk for a first non-fatal serious infection (SI). cPatients who provided at least one day of at risk for a first SI from drugs of interest. FU follow-up, TOF tofacitinib, TCs treatment courses.

Back to article page